Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 1
3 (100.0%)Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients
Phase 1
Completed
- Conditions
- Clear Cell Renal Cell Carcinoma Metastatic
- Interventions
- Drug: 68Ga-NYM005 injection
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 19
- Registration Number
- NCT06389682
- Locations
- π¨π³
Affliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
π¨π³Peking Union Medical College Hospital, Beijing, China
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 20
- Registration Number
- NCT06389695
- Locations
- π¨π³
Affliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
π¨π³Peking Union Medical College Hospital, Beijing, China
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: 177Lu-NYM032 injection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 30
- Registration Number
- NCT06383052
- Locations
- π¨π³
Affliated Hospital of Jiangnan University, Wuxi, China
News
No news found